Lupus drug anifrolumab under scrutiny for pregnancy risks

NCT ID NCT06795893

Recruiting now Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 12, 2026 · Updated 6 times

Summary

This study tracks 240 pregnant women with lupus who have taken anifrolumab (Saphnelo) to see if the drug affects pregnancy or baby health. Researchers will monitor for birth defects and other complications. The goal is to gather safety information, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: anifrolumab (Saphnelo)
What this could lead to: If successful, this study could provide crucial safety data on anifrolumab use during pregnancy, helping doctors and patients make informed decisions.
What could go wrong: This is an observational study, not a treatment trial, so it won't test if anifrolumab works. Results depend on accurate reporting and may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC LUPUS ERYTHEMATOSUS

Contacts and locations

Locations

Reseach Facility
RECRUITING

Södertälje, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.